• Online Features  This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

SALVATORE LI VOLTI, MD
Clinica Pediatrica

FELICIA DI GREGORIO, MD; GINO SCHILIRÒ, MD
Cattedra di Ematologia Pediatrica Università di Catania Citta Universitaria Viale Andrea Doria 6 95125 Catania, Italy

Am J Dis Child. 1990;144(10):1069-1070.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Sir.—Deferoxamine administration is still necessary in the management of thalassemia and, when used appropriately, it is beneficial in controlling iron overload.¹

In the past, the general assumption that deferoxamine treatment was devoid of side effects resulted in a tendency to administer high doses; the reduction of serum ferritin to below 1000 µg/L was considered an objective to pursue with determination.² However, in a review of the recent data reported in the literature,^3-6 Lo Faro et al¹ suggested that the side effects (infections, cataracts, visual-field defects, severe vision loss or more subtle signs of visual and auditory neurotoxicity, and slow growth) of this drug are dose dependent. Moreover, Schilirò and Russo⁷ asserted that normalization of serum ferritin levels in patients with thalassemia should not be the goal of the treatment and that serum ferritin levels three or four times nor . . . [Full Text PDF of this Article]

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?